Also in this ex vivo cellular model, siCHKA induced a consistent increase of TRAIL-R2 membrane exposure (Fig. 7b) thus allowing sensitization of patients-derived cancer cells to bsAb-mediated lymphocyte retargeting with a significant increase of growth inhibition (Fig. 7c). Here, TNFRSF10B is linked to cancer.